Prosexol tablets 0.5 mg for lowering testosterone level

General information on Japanese Prosexol tablets 0.5 mg for lowering testosterone level

Package details: 100 tablets

Manufacturer: ASKA Pharmaceutical Co., Ltd., Japan

Active ingredient: ethinylestradiol (chemical formula C20H24O2)

Medical effect: Prosexol tablets are effective for lowering testosterone level. They are used for treatment of the following diseases and conditions:

• female menopause,
• hypogonadism in women,
• preventing osteoporosis in elder women,
• after-menopause breast cancer in the terminal study,
• prostate cancer in men.

Contraindications and precautions: do not use in patients with estrogen-dependent malignancy, endometrial hyperplasia, pulmonary embolism or thrombophlebitis. Do not use in patients with thrombophlebitis or pulmonary embolism in history. If you take any other medication, please consult with your doctor before use.

Dosage and administration of Japanese Prosexol tablets 0.5 mg for lowering testosterone level Take 1-2 tablets 3 times a day with water. The consulting doctor may adjust the dosage according to symptoms.

How effective are Prosexol tablets 0.5 mg from Japan for lowering testosterone level?

Prosexol tablets contain ethinyl estradiol, a synthetic derivative of estradiol, with better bioavailability and resistance to metabolism and fewer side effects. It activates both isoforms of estrogen receptors and suppresses the activity of luteinizing hormone and follicle-stimulating hormone. Prosexol tablets work as a potent antiandrogen in both men and women by lowering testosterone level in blood (E. Nieschlag, H. M. Behre, S. Nieschlag Testosterone: Action, Deficiency, Substitution. Cambridge University Press, 2012, Fourth Edition. P. 62).

Who should use Prosexol tablets 0.5 mg from Japan?

Prosexol tablets can be used by both men and women. They are effective for treatment of female menopause symptoms and female hypogonadism. Prosexol tablets help to prevent osteoporosis in elderly women. Also, they are used as a part of therapy in treatment of prostate cancer in men and after-menopause breast cancer in women.